REQUEST A DEMO
Total
USD $0.00
Search more companies

OBI Pharma, Inc. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: OBI Pharma, Inc. Profile Updated: May 26, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Optimer Biotechnology, Inc. (OBI) is a biotech company was formed in Taiwan in 2002. At beginning, it’s structured as a wholly owned subsidiary of Optimer Pharmaceuticals Inc. (OPTR) in San Diego, CA, USA. In November, 2009, it was spinning off from OPTR, forming a new management team with a mission to develop novel therapeutic agents for diseases that are currently lacking treatment options. The initial therapeutic focus will be cancer and osteoarthritis. OBI is positioned as a new product development company striving to improve health and quality of life through innovative and cost effective medicine.

Headquarters
6F., No. 508, Sec. 7, Zhongxiao E. Rd, Nangang Dist
Taipei City; Taipei City;

Contact Details: Purchase the OBI Pharma, Inc. report to view the information.

Website: http://www.obipharma.com

Basic Information
Total Employees:
Purchase the OBI Pharma, Inc. report to view the information.
Outstanding Shares:
Purchase the OBI Pharma, Inc. report to view the information.
Financial Auditors:
Purchase the OBI Pharma, Inc. report to view the information.
Incorporation Date:
April 29, 2002
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chief Executive Officer
Ownership Details
Purchase this report to view the information.
11.23%
Purchase this report to view the information.
1.42%
Purchase this report to view the information.
Purchase this report to view the information.
Purchase this report to view the information.
Subsidiaries
Obi Pharma Australiapty.Ltd. (Australia)
100%
Obi Pharma Usa Inc. (United States)
100%
浩鼎醫藥生技有限公司 (Hong Kong SAR, China)
100%
Company Performance
Financial values in the chart are available after OBI Pharma, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
141.56%
Total operating revenue
N/A
Operating profit (EBIT)
-22.03%
EBITDA
N/A
Net Profit (Loss) for the Period
-1236.17%
Total assets
-29.36%
Total equity
-34.89%
Operating Profit Margin (ROS)
4182.59%
Net Profit Margin
-3364.74%
Return on Equity (ROE)
-27.8%
Debt to Equity Ratio
12.42%
Quick Ratio
-18.81%
Cash Ratio
-16.68%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?